New hope for incurable brain cancer: drug combo shows promise
NCT ID NCT03212742
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 36 times
Summary
This study tests whether adding the drug olaparib to standard radiation and chemotherapy can help people with aggressive, inoperable brain tumors live longer. About 91 participants will receive the combination treatment. The goal is to find the best dose and see if it improves survival at 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH du Havre
Le Havre, France
-
CHU
Amiens, France
-
CHU
Bordeaux, France
-
Centre Eugène Marquis
Rennes, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Guillaume le Conquérant
Le Havre, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
-
Centre léon Bérard
Lyon, France
-
GHBS
Lorient, France
-
Hôpitaux universitaires La Pitié Salpétrière - Charles Foix
Paris, France
-
Institut Claudius Regaud
Toulouse, France
-
Institut Curie
Paris, France
-
Institut de Cancérologie de l'Ouest
Angers, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, France
Conditions
Explore the condition pages connected to this study.